Effects of H1- and H2-antihistamines on platelet-activating factor and bradykinin-induced inflammatory responses in human skin
Authors: SANSOM, J.E.1; BROOKS, J.1; BURTON, J.L.1; ARCHER, C.B.1
Source: Clinical & Experimental Dermatology, Volume 21, Number 1, January 1996 , pp. 33-37(5)
Publisher: Blackwell Publishing
Key:
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Abstract:
Previous studies show that oral antihistamines affect the weal and flare response to intradermal injections of the inflammatory mediators platelet-activating factor (PAF) and bradykinin (BK). The aim of this study was to compare the effects of terfenadine (an H1-antagonist) and cimetidine (an H2-antagonist) on weal and flare responses to PAF and BK in healthy non-atopic human volunteers. The effects of doxepin on PAF responses were investigated, as there is evidence that doxepin may have direct anti-PAF effects in addition to its known antihistaminic actions. Terfenadine significantly reduced weal and flare responses to PAF (mean reduction 53 and 73%, respectively) and flare responses to BK (mean reduction 78%) but had no effect on weal responses to BK. Doxepin significantly reduced both weal and flare responses to PAF (mean reduction 43 and 68%, respectively, at higher doses of PAF). Cimetidine had no effect on weal or flare responses to PAF or BK. These findings suggest that the flare response to intradermal BK is mediated via histamine release while the weal response is not. The effects of the various antagonists of PAF-induced responses suggest that its effects too may be mediated via histamine, the similarity of the effects of terfenadine and doxepin on these responses indicating that the effects of doxepin may be due to its known antihistamine activity rather than to any specific PAF-antagonistic properties.Document Type: Research article
DOI: 10.1046/j.1365-2230.1996.d01-166.x
Affiliations: 1: Department of Dermatology, University of Bristol, Bristol Royal Infirmary, Bristol BS2 8HW, UK
Key:
- Free Content
- New Content
- Subscribed Content
- Free Trial Content

Click here for Page Help